Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02974374 · ClinicalTrials.gov registry record · Phase 1

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target

NCT02974374 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02974374, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a single dose of PF-06835919 in healthy adult subjects.

Interventions

  • OTHER Placebo
  • DRUG PF-06835919

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2016-10
Est. Completion 2017-01
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT02974374

The ClinicalTrials.gov registry entry for NCT02974374 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02974374 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02974374 about?

NCT02974374 is a clinical study titled "Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects". The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a single dose of PF-06835919 in healthy adult subjects.

What is the current status of trial NCT02974374?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-10. Estimated completion is 2017-01.

What interventions are being tested in trial NCT02974374?

The interventions under investigation include: Placebo (OTHER), PF-06835919 (DRUG).

Who is sponsoring clinical trial NCT02974374?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.